24 October 2023 - Orphelia Pharma today announces the filing of a centralised marketing authorisation application to the EMA for Kizfizo, the first oral liquid formulation of temozolomide.

Kizfizo (temozolomide oral suspension, 40 mg/ml), known as Ped-TMZ or Kimozo during its clinical development and ongoing early access programs, is designed specifically for use in the treatment of children with relapsed or refractory neuroblastoma, oncology indications with a very poor prognosis.

Read Orphelia Pharma press release